Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | FDFT1 | P37268 | 4/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119083 | 0.90 | ALDH1A1 (0.39) | LPAR1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4110496 | 0.86 | FDFT1 (0.40) | LPAR1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4128922 | 0.81 | LMNA (0.44) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL4124488 | 0.78 | ALDH1A1 (0.57) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL4117454 | 0.78 | FDFT1 (0.38) | LPAR1ALDH1A1FDFT1MAPTGAA | |
| SCHEMBL4118056 | 0.78 | ALDH1A1 (0.43) | LPAR1ALDH1A1FDFT1MAPTMEN1 | |
| SCHEMBL4118297 | 0.77 | LPAR1 (0.49) | LPAR1ALDH1A1NPC1LMNANPSR1 | |
| SCHEMBL4127705 | 0.77 | FDFT1 (0.38) | LPAR1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4111602 | 0.76 | LMNA (0.44) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL4117839 | 0.76 | TAS1R3 (0.44) | ALDH1A1SMN1; SMN2LMNAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | LPAR1 345/4885ALDH1A1 1587/4885NPC1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.